Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxalisib in newly diagnosed unmethylated MGMT glioblastoma
NCT03522298Phase 2Completed
- Sponsor
- Kazia Therapeutics
- Start
- May 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paxalisib in glioblastoma (GBM), sponsored by Kazia Therapeutics. Started May 2018; status: completed.
02
Drugs
paxalisib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03522298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03522298.